By using this site, you agree to the Privacy Policy and Terms of Use.

Notification Show More

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

10 hours ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

10 hours ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

10 hours ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

12 hours ago

Best SEO Tool (June 2025): Moz Named Top SEO Software by Software Experts

Best SEO Tool (June 2025): Moz Named Top SEO Software by Software Experts

12 hours ago

Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval

Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval

12 hours ago

LINKIN PARK ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI

LINKIN PARK ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI

17 hours ago

oneworld alliance Strengthens Leadership Team With Three Key Appointments

oneworld alliance Strengthens Leadership Team With Three Key Appointments

17 hours ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

1 day ago

Home
Automobile
Entertainment
Esports
Food
Health
Life Style
Technology
Travel

Entertainment
Technology

Search

Home
Automobile
Entertainment
Esports
Food
Health
Life Style
Technology
Travel

Have an existing account? Sign In

Follow US

Tag: (ex-china)

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

February 27, 2025 19:05 ET | Source: Nxera Pharma Cenerimod is a…

GlobeNews Wire 28/02/2025

undefined

Categories

Uncategorized
Health
Technology
Entertainment
Esports
Automobile
Travel
Food
Life Style
News

About US

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

Email address:

Leave this field empty if you’re human:

Copyright © 2021 - 2024 AdKhabar. All Rights Reserved. POWERED BY Life Care News.

Welcome Back!

Sign in to your account

Username or Email Address

Password

Remember me

Lost your password?